|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-5-12
|
|
pubmed:abstractText |
HAb18G/CD147 is a hepatocellular carcinoma (HCC)-associated antigen. We developed iodine (131I) metuximab injection (Licartin), a novel 131I-labeled HAb18G/CD147-specific monoclonal antibody Fab'2 fragment, and evaluated its safety, pharmacokinetics, and clinical efficacy on HCC in Phase I/II trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
pubmed-author:BianHui-JieHJ,
pubmed-author:BoxS JSJ,
pubmed-author:ChenZhi-NanZN,
pubmed-author:FengQiangQ,
pubmed-author:FengYuanY,
pubmed-author:JiangJian-LiJL,
pubmed-author:KuangAn-RenAR,
pubmed-author:LengNanN,
pubmed-author:LiMiM,
pubmed-author:LiYun-ChunYC,
pubmed-author:LiangDe-RongDR,
pubmed-author:LiuQing-GuangQG,
pubmed-author:LuWu-ShengWS,
pubmed-author:MiaoJiaJ,
pubmed-author:MoTing-ShuTS,
pubmed-author:NanKe-JunKJ,
pubmed-author:NazSS,
pubmed-author:NgomN NNN,
pubmed-author:QianAi-RongAR,
pubmed-author:ShangPengP,
pubmed-author:SongFeiF,
pubmed-author:TanTian-ZhiTZ,
pubmed-author:WangXian-HuiXH,
pubmed-author:WuZhen-BiaoZB,
pubmed-author:XingJin-LiangJL,
pubmed-author:XuGuo-HuiGH,
pubmed-author:XuJingJ,
pubmed-author:YangXiang-MinXM,
pubmed-author:YuLiL,
pubmed-author:YuXiao-LingXL,
pubmed-author:ZhangHong-XinHX,
pubmed-author:ZhangQingQ,
pubmed-author:ZhangSi-HeSH,
pubmed-author:ZhangZhengZ,
pubmed-author:ZhangZhi-HuiZH,
pubmed-author:ZhuPingP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
435-44
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16690431-Adolescent,
pubmed-meshheading:16690431-Adult,
pubmed-meshheading:16690431-Aged,
pubmed-meshheading:16690431-Antibodies, Monoclonal,
pubmed-meshheading:16690431-Antigens, CD147,
pubmed-meshheading:16690431-Antineoplastic Agents,
pubmed-meshheading:16690431-Carcinoma, Hepatocellular,
pubmed-meshheading:16690431-Drug Combinations,
pubmed-meshheading:16690431-Female,
pubmed-meshheading:16690431-Humans,
pubmed-meshheading:16690431-Iodine Radioisotopes,
pubmed-meshheading:16690431-Liver Neoplasms,
pubmed-meshheading:16690431-Male,
pubmed-meshheading:16690431-Maximum Tolerated Dose,
pubmed-meshheading:16690431-Middle Aged,
pubmed-meshheading:16690431-Radioimmunotherapy
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.
|
|
pubmed:affiliation |
Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
